What is Chardan Capital’s Estimate for EYPT FY2026 Earnings?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Chardan Capital issued their FY2026 earnings estimates for EyePoint Pharmaceuticals in a research report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will post earnings of ($2.82) per share for the year. Chardan Capital has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.13) per share.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The business had revenue of $11.60 million for the quarter, compared to analysts’ expectations of $11.02 million.

A number of other research firms have also recently weighed in on EYPT. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Citigroup began coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $33.00 target price for the company. Finally, StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a report on Friday, March 14th. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.63.

EyePoint Pharmaceuticals Price Performance

Shares of NASDAQ EYPT opened at $6.06 on Wednesday. EyePoint Pharmaceuticals has a 1-year low of $5.54 and a 1-year high of $23.65. The company has a market capitalization of $416.50 million, a price-to-earnings ratio of -3.03 and a beta of 1.41. The business has a 50-day moving average of $6.85 and a 200-day moving average of $8.26.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Suvretta Capital Management LLC lifted its position in shares of EyePoint Pharmaceuticals by 31.1% during the fourth quarter. Suvretta Capital Management LLC now owns 6,783,091 shares of the company’s stock worth $50,534,000 after purchasing an additional 1,607,268 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in EyePoint Pharmaceuticals by 51.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company’s stock valued at $42,838,000 after buying an additional 1,958,580 shares in the last quarter. Franklin Resources Inc. grew its position in shares of EyePoint Pharmaceuticals by 3.1% in the 4th quarter. Franklin Resources Inc. now owns 4,137,567 shares of the company’s stock worth $30,825,000 after acquiring an additional 125,519 shares in the last quarter. Vanguard Group Inc. grew its position in shares of EyePoint Pharmaceuticals by 24.8% in the 4th quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company’s stock worth $28,334,000 after acquiring an additional 755,045 shares in the last quarter. Finally, Federated Hermes Inc. increased its holdings in shares of EyePoint Pharmaceuticals by 92.7% in the 4th quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company’s stock valued at $27,620,000 after acquiring an additional 1,783,765 shares during the last quarter. Institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.